Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bausch + Lomb Corporation (BLCO : NYSE)

• Company Description    Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R). Bausch Lomb Corporation is based in VAUGHAN, ON. Number of Employees: 13,500

• Price / Volume Information    Yesterday's Closing Price: $15.32 Daily Weekly Monthly 20 Day Moving Average: 500,092 shares Shares Outstanding: 354.04 (millions) Market Capitalization: $5,423.95 (millions) Beta: 0.63 52 Week High: $21.69 52 Week Low: $10.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.81% 6.84% 12 Week 32.64% 20.43% Year To Date -15.17% -24.26%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 520 APPLEWOOD CRESCENT - VAUGHAN,A6 L4K 4B4 CAN ph: 905-695-7700 fax: - None http://www.bausch.com

• General Corporate Information    Officers Brenton L. Saunders - Chairman of the Board and Chief Executive Officer Sam Eldessouky - Executive Vice President and Chief Financial Offic Frederick J. Munsch - Senior Vice President; Controller and Chief Accoun Brett Icahn - Director Gary Hu - Director Peer Information Bausch + Lomb Corporation (CHCR) Bausch + Lomb Corporation (ESRX) Bausch + Lomb Corporation (MYDP) Bausch + Lomb Corporation (COR) Bausch + Lomb Corporation (GBCS) Bausch + Lomb Corporation (LAXAF) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: Medical Services Sector: Medical CUSIP: 071705107 SIC: 3851 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 10/29/25 Share - Related Items Shares Outstanding: 354.04 Most Recent Split Date: (:1) Beta: 0.63 Market Capitalization: $5,423.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.16 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.55 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 17.91% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/29/25

• Fundamental Ratios P/E Current FY Estimate: 27.93 Trailing 12 Months: 36.48 PEG Ratio: 1.56 Price Ratios Price/Book: 0.83 Price/Cash Flow: 8.18 Price / Sales: 1.11 EPS Growth vs. Year Ago Period: -46.15% vs. Previous Quarter: 200.00% Sales Growth vs. Year Ago Period: 5.10% vs. Previous Quarter: 12.40% ROE 06/30/25 - 2.33 03/31/25 - 2.62 12/31/24 - 3.35 ROA 06/30/25 - 1.12 03/31/25 - 1.28 12/31/24 - 1.66 Current Ratio 06/30/25 - 1.55 03/31/25 - 1.56 12/31/24 - 1.60 Quick Ratio 06/30/25 - 0.98 03/31/25 - 0.96 12/31/24 - 1.01 Operating Margin 06/30/25 - 3.11 03/31/25 - 3.56 12/31/24 - 4.63 Net Margin 06/30/25 - -5.58 03/31/25 - -7.50 12/31/24 - -6.62 Pre-Tax Margin 06/30/25 - -8.08 03/31/25 - -6.71 12/31/24 - -4.88 Book Value 06/30/25 - 18.39 03/31/25 - 18.20 12/31/24 - 18.57 Inventory Turnover 06/30/25 - 1.86 03/31/25 - 1.81 12/31/24 - 1.74 Debt-to-Equity 06/30/25 - 0.76 03/31/25 - 0.74 12/31/24 - 0.72 Debt-to-Capital 06/30/25 - 43.11 03/31/25 - 42.67 12/31/24 - 42.03

Powered by Zacks Investment Research ©